Decision Resources, Inc., one of the world's leading research and advisory firms focusing on pharmaceutical and health care issues, finds that Genentech/Roche's Avastin will account for more than 50% of the non-small-cell lung cancer drug market in 2014.

"Novel, targeted biological therapies, such as the anti-angiogenic monoclonal antibody bevacizumab (Genentech/Roche's Avastin), will further expand treatment options for advanced disease," said Mohammed Muhsin, analyst at Decision Resources, Inc. "Avastin will be launched in 2006 and will be the main driver of the non-small-cell lung cancer market from 2009 to 2014."

The new Pharmacor study entitled Non-Small-Cell Lung Cancer also finds that generics erosion will threaten three major drugs in the non-small-cell lung cancer drug market. The recent patent expiry of carboplatin in the United States and patient expiries of Sanofi-Aventis's docetaxel and Eli Lilly's gemcitabine in the United States and other markets will constrain the market value of these agents.

About Non-Small-Cell Lung Cancer

Lung cancer is the leading cancer in the industrialized nations and is becoming increasingly prevalent in developing countries. Non-small-cell lung cancer, a heterogeneous disease encompassing several types of lung cancer, accounts for 80-85% of lung cancers. The five-year survival rate, owing to a correspondingly high mortality rate, is less than 15%. Non-small-cell lung cancer accounts for 25% of all cancer deaths in women and more than 30% of cancer deaths in men.

About Pharmacor from Decision Resources

Pharmacor is a unique family of studies that assesses a host of market- impacting factors and analyzes the commercial outlook for drugs in research and development.

About Decision Resources

Decision Resources, Inc., ( is a world leader in market research publications, advisory services, and consulting designed to help clients shape strategy, allocate resources, and master their chosen markets.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

   For more information, contact:     Elizabeth Marshall    Decision Resources, Inc.    781-296-2563 

SOURCE: Decision Resources, Inc.

CONTACT: Elizabeth Marshall of Decision Resources, Inc.,

Michigan HMOs Garner Smaller Profits in 2004

View Now